NCT03550482 is a Phase 4 clinical trial of ONCOXIN® in Gastric Cancer Stage II, sponsored by Catalysis SL.

Who is sponsoring NCT03550482?

NCT03550482 is sponsored by Catalysis SL.

What drugs are being tested in NCT03550482?

Interventions in NCT03550482: ONCOXIN®.

What condition does NCT03550482 study?

NCT03550482 studies Gastric Cancer Stage II, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Gastric Cancer Stage III.

Is NCT03550482 still recruiting?

NCT03550482 is currently completed. Last updated 5 June 2019.

Last reviewed 2019-06-05 · How we verify

NCT03550482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oncoxin® and Quality of Life in Cancer Patients

Completed Phase 4 Last updated 5 June 2019

What this trial tests

Phase 4 trial testing ONCOXIN® in Gastric Cancer Stage II in 133 participants. Completed in 15 May 2019.

Timeline

1 November 2017

Primary endpoint
15 March 2019

15 May 2019

Quick facts

Lead sponsor	Catalysis SL
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	133
Start date	1 November 2017
Primary completion	15 March 2019
Estimated completion	15 May 2019
Sites	9 locations across Kazakhstan, Russia

Drugs / interventions tested

ONCOXIN®

Conditions studied

Gastric Cancer Stage II — all drugs for Gastric Cancer Stage II →
Non-small Cell Lung Cancer Stage II — all drugs for Non-small Cell Lung Cancer Stage II →
Non-small Cell Lung Cancer Stage III — all drugs for Non-small Cell Lung Cancer Stage III →
Gastric Cancer Stage III — all drugs for Gastric Cancer Stage III →

Sponsor

Catalysis SL — full company profile →

Who can join

Adults 50 to 70, any sex, with Gastric Cancer Stage II or Non-small Cell Lung Cancer Stage II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments. Food supplement ONCOXIN (ONCX) contains amino acids, vitamins, minerals and biologically active substances of natural origin with high immunostimulatory and antioxidant activity. Present study is a real world experience study intended to evaluate the efficacy of ONCX in cancer patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.
Cencioni C, Trestini I, Piro G, Bria E, et al · · 2022 · cited 24× · PMID 35458104 · DOI 10.3390/nu14081542
Antitumoral Properties of the Nutritional Supplement Ocoxin Oral Solution: A Comprehensive Review.
Pandiella-Alonso A, Díaz-Rodríguez E, Sanz E. · · 2020 · cited 8× · PMID 32878230 · DOI 10.3390/nu12092661
Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy.
Kaidarova DR, Kopp MV, Pokrovsky VS, Dzhugashvili M, et al · · 2019 · cited 7× · PMID 31641390 · DOI 10.3892/ol.2019.10868

Verify or expand the search:

Other recruiting trials for Gastric Cancer Stage II

Currently open trials in the same condition.

NCT06755554 — Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer · Phase 3 · recruiting
NCT06042998 — A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer · NA · recruiting

Other Catalysis SL trials

Trials by the same sponsor.

NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03550482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
Last refreshed: 5 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03550482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing